AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37745371
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg twice daily for 12 days (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Trial: 37746735
Drug: Brensocatib 10
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 10 mg, 25 mg, and Placebo
Trial: 37746735
Drug: Brensocatib 10
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 10 mg and 25 mg
Trial: 37747168
Drug: 24-hour intravenous
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour intravenous administration of antibiotics
Trial: 37747168
Drug: 24-hour oral
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour oral administration of antibiotics
Trial: 37747427
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (preoperative use)
Trial: 37747970
Drug: Mental health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental health intervention including case management, psychotropic medication consultation, and psychotherapy elements.
Trial: 37748109
Drug: Nine-week trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine-week trastuzumab treatment
Trial: 37748109
Drug: One-year trastuzumab
RxNorm normalized name: segesterone
DrugBank: Segesterone (DB14584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-year trastuzumab treatment
Trial: 37748124
Drug: Prophylactic Radiation
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic Radiation Therapy (RT)
Trial: 37748181
Drug: OD analogues
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OD analogues (insulin degludec, insulin glargine U100, or insulin glargine U300)
Trial: 37748693
Drug: Avelumab Q2W
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab Q2W (10 mg/kg every 2 weeks)
Trial: 37748693
Drug: Avelumab QW
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab QW (10 mg/kg once weekly for 12 weeks, then Q2W)
Trial: 37748849
Drug: Empiric antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotic use
Trial: 37748849
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of probiotics
Trial: 37749876
Drug: Acceptance-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based behavioral treatment for insomnia
Trial: 37750183
Drug: Evogliptin 5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin 5 mg once daily
Trial: 37750406
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg
Trial: 37750406
Drug: vonoprazan 40
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: vonoprazan 40 mg
Trial: 37750660
Drug: Sequential exercise-cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential exercise-cognitive training (SEQ)
Trial: 37750695
Drug: Oral tedizolid
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tedizolid treatment for BJIs
Trial: 37751016
Drug: Gepotidacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin (2 × 3000 mg 10-12 h apart)
Trial: 37751016
Drug: Ceftriaxone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (500 mg, intramuscular) plus Azithromycin (1 g, oral)
Trial: 37751015
Drug: AZD7442 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (600 mg)
Trial: 37751019
Drug: Fostemsavir +
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir + Optimized Background Therapy (OBT)
Trial: 39368039
Drug: Tucatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib (300 mg twice daily)
Trial: 37751153
Drug: Intranasal glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal glucagon administration
Trial: 37751153
Drug: Injectable glucagon
RxNorm normalized name: glucagon Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable glucagon administration
Trial: 37751237
Drug: Just-in-time adaptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Just-in-time adaptive interventions (JITAIs) with notifications delivered up to 4 times per day and suggested daily step goals
Trial: 37751286
Drug: Mindfulness Treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness Treatment (MT)
Trial: 37751301
Drug: Exendin 9-39
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin 9-39 (GLP-1 Receptor antagonist)
Trial: 37751561
Drug: Tucatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib (300 mg orally twice daily) and Trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks)
Trial: 37751891
Drug: Nirmatrelvir 100
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nirmatrelvir 100 mg with ritonavir 100 mg administered 12 hours before, together with, and 12 and 24 hours after nirmatrelvir
Trial: 37752423
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg/day continuously plus lanreotide 120 mg every 28 days
Trial: 37752816
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)
Trial: 37752816
Drug: TAF 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B)
Trial: 37752816
Drug: Intensified four-drug
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified four-drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C)
Trial: 37753461
Drug: Adaptive FDG-PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive FDG-PET/CT response-guided radiotherapy (total dose 70-78 Gy)
Trial: 37753808
Drug: TPMT-NUDT15 gene-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPMT-NUDT15 gene-based dosing of 6-MP (10 to 50 mg/m2)
Trial: 37753808
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard dosing of 6-MP)
Trial: 37754283
Drug: Tight glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glucose control (blood-glucose level targeted at 80 to 110 mg per deciliter)
Trial: 37754283
Drug: Liberal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal glucose control (insulin initiated only when blood-glucose level was >215 mg per deciliter)
Trial: 37754485
Drug: Camu camu
RxNorm normalized name: CAMUSTINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camu camu (CC) added to nivolumab
Trial: 37754682
Drug: Maternal antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antibodies at birth
Trial: 37755151
Drug: Neurofeedback (NF)
RxNorm normalized name: NFS-02
DrugBank: NFS-02 (DB18422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback (NF) treatment, 12 sessions
Trial: 37755506
Drug: Bleach baths
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleach baths (0.005% NaClO; 5-10 min duration) twice a week for 12 weeks
Trial: 37756532
Drug: Ibrutinib maintenance
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib maintenance (I-M) 560 mg daily for up to 4 years
Trial: 37758574
Drug: Nivolumab maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab maintenance therapy (intravenous nivolumab 8 × 240 mg every 2 weeks, followed by 480 mg every 4 weeks)
Trial: 37758574
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor (TKI) maintenance therapy (sunitinib 50 mg or pazopanib 800 mg once daily)
Trial: 37758623
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural bupivacaine with morphine
Trial: 37758649
Drug: Community-based adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based adherence support intervention for daily oral PrEP
Trial: 37758676
Drug: Pain Neuroscience
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Neuroscience Education (PNE) combined with conventional treatment, 9 sessions (1 session/week for 9 weeks), each lasting 30-40 min
Trial: 37758676
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (pharmacological treatment)
Trial: 37758711
Drug: Pre-treatment immunogenicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment immunogenicity analysis
Trial: 37758864
Drug: Culture negative
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture negative sepsis with 5 days of antibiotics
Trial: 37759099
Drug: Biologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic therapy achieving PASI90
Trial: 37759324
Drug: Personalized multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized multimodal treatment (individualized physical exercise program combined with individualized nutritional therapy) for 12 weeks
Trial: 37759489
Drug: PARPi-niraparib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARPi-niraparib therapy
Trial: 37765023
Drug: High-dose Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Dexamethasone (HD-DXM)
Trial: 37766218
Drug: Ultra-sensitive targeted
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-sensitive targeted PCR assay coupled with next-generation sequencing (NGS) for characterising HIV-1 DNA drug resistance mutations (DRMs).
Trial: 37766505
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment (SOC)
Trial: 37766731
Drug: Sustained-release β-alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release β-alanine (15 g/day divided into 3 intakes for 30 days)
Trial: 37766731
Drug: Sustained-release β-alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release β-alanine
Trial: 37767191
Drug: Anlotinib maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib maintenance treatment
Trial: 37767195
Drug: Treat-to-target strategy
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target strategy with a target LDL-C level of 50-70 mg/dL
Trial: 39314261
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin treatment
Trial: 37767823
Drug: Sham bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham bright light therapy
Trial: 37768018
Drug: Sex chromosome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex chromosome dosage (SCD)
Trial: 37768317
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (40 mg/kg daily, RIF40)
Trial: 37768317
Drug: Standard-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose rifampicin (10 mg/kg daily, RIF10)
Trial: 37768658
Drug: Tiragolumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (2 mg escalating to 1200 mg) in phase 1a and combination with Atezolizumab (1200 mg every 3 weeks) in phase 1b
Trial: 37768658
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tiragolumab plus Atezolizumab
Trial: 37768670
Drug: CRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT plus lapatinib (1500 mg per day)
Trial: 37768671
Drug: Eplontersen (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplontersen (45 mg every 4 weeks; n=144)
Trial: 37769181
Drug: Irbesartan/hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks, respectively.
Trial: 37769181
Drug: Irbesartan/hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/hydrochlorothiazide combination treatment.
Trial: 37769308
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (oral 650 mg acetaminophen and 200 mg caffeine)
Trial: 37769428
Drug: Inebilizumab 300
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inebilizumab 300 mg IV on Days 1 and 15
Trial: 37769429
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA vaccine (2 or 3 doses after ≥1 month of subcutaneous ofatumumab 20 mg/month)
Trial: 37769429
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA vaccine (3 doses)
Trial: 37769429
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA vaccine (2 doses)
Trial: 37769429
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA vaccine (for patients aged <40 years without previous anti-CD20 therapy)
Trial: 37769610
Drug: Internal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine residents interpreting SL-ECGs
Trial: 37770120
Drug: Intranasal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sufentanil
Trial: 37770120
Drug: Oral/intravenous opioids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/intravenous opioids
Trial: 37770132
Drug: Noninvasive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive therapies (silver diamine fluoride, self-assembling peptide P)
Trial: 37770132
Drug: Noninvasive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive therapies (including self-assembling peptide P)
Trial: 37770132
Drug: Hypothetical scenarios
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical scenarios with noninvasive therapies
Trial: 37770278
Drug: Short screening
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short screening for CRF using five items at high frequency during therapy and lower frequency during post-treatment phase for 18 months
Trial: 37770309
Drug: Delayed-release/extended-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release/extended-release methylphenidate (DR/ER-MPH)
Trial: 37770652
Drug: Garetosmab (activin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garetosmab (activin A-blocking antibody)
Trial: 37770704
Drug: High-FN-risk chemotherapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-FN-risk chemotherapy regimen
Trial: 37770704
Drug: Low and
RxNorm normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low and intermediate FN-risk chemotherapy regimens
Trial: 37770881
Drug: Mind-body and
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body and Art Therapies (MBATs)
Trial: 37770889
Drug: Benralizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab treatment
Trial: 37770944
Drug: VISA-G-Norwegian questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VISA-G-Norwegian questionnaire
Trial: 37771545
Drug: Glecaprevir-pibrentasvir 300
RxNorm normalized name: glecaprevir / pibrentasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 4 weeks
Trial: 37772282
Drug: Deutetrabenazine (6-48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (6-48 mg daily)
Trial: 37772436
Drug: PF-06817024 (10-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06817024 (10-1000 mg single intravenous doses)
Trial: 37772436
Drug: PF-06817024 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06817024 (single dose)
Trial: 37772436
Drug: PF-06817024 (repeat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06817024 (repeat doses)
Trial: 37772436
Drug: PF-06817024 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06817024 (single intravenous administration)
Trial: 37773184
Drug: Monovalent COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent COVID-19 vaccines
Trial: 37773189
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID vs 10 mg BID
Trial: 37773600
Drug: Treatment (rehabilitation)
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (rehabilitation)
Trial: 37773624
Drug: Routine preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine preparations (CG)
Trial: 37774185
Drug: Lidocaine 2mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2mg/kg with saline infusion (GL)
Trial: 37774185
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg duloxetine (GD)
Trial: 37774185
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline infusion (GC)
Trial: 37774188
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine infusion (LDKI) at 0.1 mg/kg/h
Trial: 37774508
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2)
Trial: 37774646
Drug: Standard systolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systolic blood pressure treatment to goal < 140 mm Hg
Trial: 37774646
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (CCB) exposure
Trial: 37774729
Drug: Single-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose inactivated poliovirus vaccine (IPV)
Trial: 37775297
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral semaglutide therapy
Trial: 37775297
Drug: 2-year delay
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-year delay in oral semaglutide therapy
Trial: 37775521
Drug: PHH-1V vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHH-1V vaccine formulations 10 µg
Trial: 37775521
Drug: PHH-1V vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHH-1V vaccine formulations 20 µg
Trial: 37775521
Drug: PHH-1V vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHH-1V vaccine formulations 40 µg
Trial: 37775584
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing green tea extract and hyaluronic acid applied 3 times a day for 7 days
Trial: 37775584
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel applied 3 times a day for 7 days
Trial: 37775744
Drug: Fuzuloparib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib 100 mg bid plus apatinib 500 mg qd
Trial: 37776194
Drug: Individualized heparin-protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized heparin-protamine titration (IHPT)
Trial: 37776235
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy (infliximab and adalimumab)